# A Clinical Trial of EYE201/MK-8748 in People With Macular Degeneration (MK-8748-002)

> **NCT07440225** · PHASE2,PHASE3 · RECRUITING · sponsor: **EyeBiotech Ltd.** · enrollment: 960 (estimated)

## Conditions studied

- Macular Degeneration
- Age-Related Macular Degeneration
- Choroidal Neovascularization
- Wet Macular Degeneration

## Interventions

- **DRUG:** Tiespectus
- **DRUG:** Aflibercept

## Key facts

- **NCT ID:** NCT07440225
- **Lead sponsor:** EyeBiotech Ltd.
- **Sponsor class:** INDUSTRY
- **Phase:** PHASE2,PHASE3
- **Study type:** INTERVENTIONAL
- **Status:** RECRUITING
- **Start date:** 2026-03-27
- **Primary completion:** 2028-06-30
- **Final completion:** 2028-06-30
- **Target enrollment:** 960 (ESTIMATED)
- **Last updated:** 2026-05-04


## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT07440225

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT07440225, "A Clinical Trial of EYE201/MK-8748 in People With Macular Degeneration (MK-8748-002)". Retrieved via AI Analytics 2026-06-25 from https://api.ai-analytics.org/clinical/NCT07440225. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*